Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Halozyme Therapeutics, Inc. - Common Stock (NQ:HALO)

54.54 +0.79 (+1.47%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Halozyme Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Halozyme Buys Antares In $960M Deal To Create One Drug Delivery, Specialty Product Entity
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Rise and shine, trader! Join me today as we break down all the news behind the biggest pre-market stock movers for Wednesday! 
Via InvestorPlace
Janssen Partner Genmab Loses Arbitration Over Darzalex Royalties
Via Benzinga
Halozyme, Chugai Ink $185M ENHANZE Technology Licensing Pact
Halozyme Therapeutics Inc (NASDAQ: HALO) has  
Via Benzinga
Argenx's Subcutaneous Efgartigimod At Par With Intravenous Administration In Neuromuscular Disorder
Argenx SE (NASDAQ: ARGX) ) has  
Via Benzinga
Earnings Scheduled For February 22, 2022
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is projected to report quarterly earnings at $0.13 per share on revenue of $439.63 million. • Sohu... 
Via Benzinga
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
Via Benzinga
Exposures Product Safety
Halozyme's Q4 Earnings Beat Consensus Despite Lower Product Sales Hit Topline Growth
Halozyme Therapeutics Inc (NASDAQ: HALO) reported Q4 revenue of $102 million compared to $121.7 million a year ago, beating the consensus of $100.32 million.... 
Via Benzinga
Halozyme Therapeutics: Q4 Earnings Insights
Halozyme Therapeutics (NASDAQ:HALO) reported its Q4 earnings results on Tuesday, February 22, 2022 at 04:00 PM. Here's what investors need to know about the announcement.... 
Via Benzinga
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers BioLine Rx (NASDAQ:BLRX) shares moved upwards by 23.65% to $2.81 during Friday's regular session. As of 12:30 EST, BioLine Rx's stock is trading at a... 
Via Benzinga
The Daily Biotech Pulse: Lilly Sings Metabolic Disorder Drug Pact, Moderna Reports Positive Flu Vaccine Data, Halozyme To Buy Back Shares
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Angion Biomedica's ANG-3777 Does Not Meet Primary Endpoint In Mid-Stage... 
Via Benzinga
7 Best Drug Stocks to Buy for 2022 Without Covid Catalysts
These seven drug stocks, a mix of growth, value, and moonshot plays, each stand to see big moves in the next twelve months. 
Via InvestorPlace
Exposures COVID-19
Janssen's Subcutaneous Darzalex Combo Wins FDA Approval For Pretreated Multiple Myeloma
Johnson & Johnson's (NYSE: JNJ) Janssen Biotech Inc has received FDA approval for Darzalex Faspro (daratumumab and hyaluronidase-fihj) in combination with... 
Via Benzinga
Exposures Product Safety
Halozyme's Q3 Sales Boosted By Darzalex; Lifts FY21 Earnings Outlook
Halozyme Therapeutics Inc (NASDAQ: HALO) reported Q3 revenue of $115.8 million compared to $65.3 million a year ago, beating the consensus of $101.94 million.... 
Via Benzinga
Halozyme Therapeutics, inc (HALO) Q3 2021 Earnings Call Transcript
HALO earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus SAB Spikes On Analyst Action SAB Biotherapeutics, Inc. (NASDAQ: SABS) shares... 
Via Benzinga
Exposures COVID-19
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 9) Adagio Therapeutics, Inc. (... 
Via Benzinga
Exposures COVID-19
Halozyme Stock Gains As Q2 Earnings Top Estimates On Higher Milestone, Royalty; Lifts FY21 Guidance
Halozyme Therapeutics Inc (NASDAQ: HALO) reported Q2 revenue of $136.5 million compared to $55.2 million a year ago, beating the consensus of $103.16 million.... 
Via Benzinga
Halozyme Therapeutics, inc (HALO) Q2 2021 Earnings Call Transcript
HALO earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Halozyme Therapeutics: Q2 Earnings Insights
Shares of Halozyme Therapeutics (NASDAQ:HALO) rose in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 247.37% over the... 
Via Benzinga
Analyzing Halozyme Therapeutics's Unusual Options Activity
On Friday, shares of Halozyme Therapeutics (NASDAQ:HALO) saw unusual options activity. After the option alert, the stock price moved down to $42.55. Sentiment: BEARISH Option... 
Via Benzinga
Janssen's Darzalex Faspro Wins FDA Approval In Combination With Pomalidomide, Dexamethasone For Multiple Myeloma
The FDA has approved Janssen Biotech Inc's, a unit of Johnson & Johnson (NYSE: JNJ) Darzalex Faspro (daratumumab and hyaluronidase-fihj) for multiple... 
Via Benzinga
Exposures Product Safety
GSK- Pfizer's ViiV To Develop 'Ultra-Long-Acting' HIV Drugs With $215M Halozyme Deal
GlaxoSmithKline plc (NYSE: GSK), Pfizer Inc (NYSE: PFE), and Shionogi Limited owned ViiV Healthcare has collaborated with Halozyme... 
Via Benzinga
The Daily Biotech Pulse: Sanofi, Translate Bio Start Early Stage Seasonal Flu Vaccine Study, Dr. Reddy's Launches Generic Vascepa, Halozyme Strikes Licensing Deal
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 21) Agios Pharmaceuticals, Inc... 
Via Benzinga
ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE® drug delivery technology to enable development of “ultra long-acting” medicines for HIV
From ViiV Healthcare
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2021
Upgrades Piper Sandler upgraded the previous rating for Boston Properties Inc (NYSE:BXP) from Neutral to Overweight. Boston Properties earned $1.56 in the first quarter,... 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Nymox Pharmaceutical (NASDAQ:NYMX... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 17, 2021
Upgrades B of A Securities upgraded the previous rating for Kosmos Energy Ltd (NYSE:KOS) from Neutral to Buy. In the first quarter, Kosmos Energy showed an EPS of $0.08,... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.